Artia Global Partners’s Neurocrine Biosciences NBIX Stock Holding History

Artia Global Partners’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-14,700	Closed	-$1.63M	–	42
2025 Q1	$1.63M	Sell	14,700 -30,300	-67%	-$3.84M	0.41%	27
2024 Q4	$6.14M	Hold	45,000	–	–	2.2%	18
2024 Q3	$5.18M	Hold	45,000	–	–	1.41%	14
2024 Q2	$6.2M	Hold	45,000	–	–	1.2%	15
2024 Q1	$6.21M	Hold	45,000	–	–	1.25%	14
2023 Q4	$5.93M	Hold	45,000	–	–	1.73%	12
2023 Q3	$5.06M	Hold	45,000	–	–	2.1%	14
2023 Q2	$4.24M	Hold	45,000	–	–	1.46%	20
2023 Q1	$4.55M	Hold	45,000	–	–	1.68%	17
2022 Q4	$5.37M	Buy	+45,000	New	+$5.27M	2.05%	12

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Artia Global Partners's NBIX Position: Q2 2025 in Review

Artia Global Partners sold out of Neurocrine Biosciences (NBIX) in Q2 2025, closing a stake of 14,700 shares — an estimated $1.63M sold.

Artia Global Partners first reported a position in NBIX in Q4 2022 and held it in 10 quarters. The position peaked at $6.21M in Q1 2024. 585 funds tracked by Wall St. Rank hold NBIX as of Q2 2025.

Artia Global Partners reported no remaining Neurocrine Biosciences position as of Q2 2025 after selling out during the quarter.
Artia Global Partners sold 14,700 Neurocrine Biosciences shares in Q2 2025, an estimated $1.63M.
Artia Global Partners first reported a position in Neurocrine Biosciences in Q4 2022 and held it in 10 quarters.
Artia Global Partners's Neurocrine Biosciences position peaked at $6.21M in Q1 2024.
585 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2025.

Based on Artia Global Partners's 13F filing for Q2 2025, filed 14 Aug 2025.